Strides Pharma Science Posts 82% Profit Surge in Q2 FY26

Strides Pharma Science Ltd recorded an impressive 82% surge in consolidated net profit for the second quarter of FY26, achieving Rs 131.52 crore. This financial milestone was primarily driven by robust revenue growth in 'other regulated markets' and efficient cost management strategies.

In a regulatory filing, the company revealed that last year's corresponding quarter saw a net profit of Rs 72.3 crore. The consolidated revenue from operations in the second quarter was Rs 1,220.83 crore, up from Rs 1,166.93 crore in the same period a year ago. Total expenses came in at Rs 1,085.03 crore, slightly reduced from Rs 1,104.61 crore the previous year.

Strides Pharma's MD and CEO, Badree Komandur, attributed the company's success to its performance in 'other regulated markets', where revenue reached USD 44 million, marking a 16% increase. The US market also saw a 2% growth in revenue, despite strong competition. Additionally, emerging markets, including Africa, LATAM, MENA, and APAC, contributed USD 17 million, a 7% increase.